基线和治疗中出现的贝达喹啉耐药性在耐药性肺结核中的：系统评价和荟萃分析。
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.
机构信息
CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
Division of Pulmonology and Critical Care, Department of Medicine, University of KwaZulu-Natal, Durban, South Africa.
出版信息
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00639-2023. Print 2023 Dec.
Abstract
Bedaquiline resistance is a major threat to drug-resistant tuberculosis control strategies. This analysis found a pooled prevalence of baseline bedaquiline resistance of 2.4% and a pooled prevalence of treatment-emergent bedaquiline resistance of 2.1%. https://bit.ly/3FC6yio
摘要
贝达喹啉耐药性是耐药结核病控制策略的主要威胁。本分析发现，基线时贝达喹啉耐药性的 pooled prevalence 为 2.4%，治疗中出现的贝达喹啉耐药性的 pooled prevalence 为 2.1%。https://bit.ly/3FC6yio
相似文献
1
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00639-2023. Print 2023 Dec.
2
Multidrug-resistant tuberculosis and bedaquiline.
N Engl J Med. 2014 Dec 18;371(25):2435-6. doi: 10.1056/NEJMc1412235.
3
Multidrug-resistant tuberculosis and bedaquiline.
N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235.
4
Rapid emergence of bedaquiline resistance: lessons to avoid repeating past errors.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01719-2016. Print 2017 Mar.
5
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196.
6
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.
N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121.
7
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.
8
Bedaquiline for the treatment of drug-resistant tuberculosis.
Expert Rev Anti Infect Ther. 2015 May;13(5):535-53. doi: 10.1586/14787210.2015.1021785. Epub 2015 Mar 22.
9
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.
10
Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568. doi: 10.1164/rccm.201909-1819LE.
引用本文的文献
1
REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENT.
Trans Am Clin Climatol Assoc. 2025;135:269-280.
2
Clinical best practices for caring for people with expanded resistance to newer TB drugs.
IJTLD Open. 2025 Jun 13;2(6):315-323. doi: 10.5588/ijtldopen.25.0240. eCollection 2025 Jun.
3
New Triazolopyrimidines with Improved Activity against .
ACS Med Chem Lett. 2025 May 1;16(6):1008-1016. doi: 10.1021/acsmedchemlett.5c00073. eCollection 2025 Jun 12.
4
Strategies for shortening tuberculosis therapy.
Nat Med. 2025 Jun;31(6):1765-1775. doi: 10.1038/s41591-025-03742-3. Epub 2025 Jun 13.
5
Identification of novel leucyl-tRNA synthetase inhibitors with antibacterial activity.
Future Med Chem. 2025 Apr;17(7):757-765. doi: 10.1080/17568919.2025.2485673. Epub 2025 Apr 21.
6
Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
BMJ Glob Health. 2025 Apr 7;10(4):e018220. doi: 10.1136/bmjgh-2024-018220.
7
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
Lancet Glob Health. 2024 Oct;12(10):e1629-e1637. doi: 10.1016/S2214-109X(24)00284-5. Epub 2024 Aug 16.
8
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance.
Emerg Infect Dis. 2024 Aug;30(8):1571-1579. doi: 10.3201/eid3008.240541.
9
A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for complex.
Eur Respir J. 2024 Jul 11;64(1). doi: 10.1183/13993003.00391-2024. Print 2024 Jul.
10
Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.
Emerg Infect Dis. 2024 Mar;30(3):568-571. doi: 10.3201/eid3003.240134.
本文引用的文献
1
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20.
2
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430.
3
Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review.
JAC Antimicrob Resist. 2022 Mar 29;4(2):dlac029. doi: 10.1093/jacamr/dlac029. eCollection 2022 Apr.
4
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12.
5
Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan.
Front Microbiol. 2021 Oct 22;12:754249. doi: 10.3389/fmicb.2021.754249. eCollection 2021.
6
Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates.
J Clin Microbiol. 2022 Jan 19;60(1):e0291920. doi: 10.1128/JCM.02919-20. Epub 2021 Oct 27.
7
Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis.
Nat Commun. 2020 Nov 30;11(1):6092. doi: 10.1038/s41467-020-19959-4.
8
Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Lancet Microbe. 2020 Aug;1(4):e165-e174. doi: 10.1016/S2666-5247(20)30031-8.
9
Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
Clin Infect Dis. 2021 Nov 2;73(9):e3391-e3397. doi: 10.1093/cid/ciaa1002.
10
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
Zotero 插件